Bone Therapeutics: Transparency notification received from Mr. J. Reymann Read more about Bone Therapeutics: Transparency notification received from Mr. J. Reymann
Bone Therapeutics: Information on the total number of voting rights and shares Read more about Bone Therapeutics: Information on the total number of voting rights and shares
Bone Therapeutics successfully raises EUR 8.5 million Read more about Bone Therapeutics successfully raises EUR 8.5 million
Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds Read more about Bone Therapeutics to raise capital through private placement of new shares and issuance of non-dilutive subordinated bonds
Bone Therapeutics: Information on the total number of voting rights and shares (June 2019) Read more about Bone Therapeutics: Information on the total number of voting rights and shares (June 2019)
Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion Read more about Bone Therapeutics’ allogeneic cell therapy product ALLOB meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion
Bone Therapeutics announces results of Annual General Meeting Read more about Bone Therapeutics announces results of Annual General Meeting
Bone Therapeutics to participate in upcoming conferences Read more about Bone Therapeutics to participate in upcoming conferences
Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel Read more about Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel